BITHIONOL
| SMILES | Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O |
| InChIKey | JFIOVJDNOJYLKP-UHFFFAOYSA-N |
Chemical properties
| Hydrogen bond acceptors | 3 |
| Hydrogen bond donors | 2 |
| Rotatable bonds | 2 |
| Molecular weight (Da) | 353.9 |
Drug properties
| Molecular type | Small molecule |
| Physiological/Surrogate | Surrogate |
| Approved drug | No |
Database connections
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| NK2 | NK2R | Human | Tachykinin | A | pKi | 5.81 | 5.81 | 5.81 | ChEMBL |
| α2B | ADA2B | Human | Adrenoceptors | A | pKi | 6.25 | 6.25 | 6.25 | ChEMBL |
| α2C | ADA2C | Human | Adrenoceptors | A | pKi | 6.2 | 6.2 | 6.2 | ChEMBL |
| 5-HT1A | 5HT1A | Rat | 5-Hydroxytryptamine | A | pKi | 5.5 | 5.5 | 5.5 | ChEMBL |
| α2A | ADA2A | Human | Adrenoceptors | A | pKi | 5.84 | 5.84 | 5.84 | ChEMBL |
| 5-HT2B | 5HT2B | Human | 5-Hydroxytryptamine | A | pKi | 5.37 | 5.37 | 5.37 | ChEMBL |
| 5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pKi | 5.34 | 5.34 | 5.34 | ChEMBL |
| D3 | DRD3 | Human | Dopamine | A | pKi | 5.84 | 5.84 | 5.84 | ChEMBL |
| A3 | AA3R | Human | Adenosine | A | pKi | 6.33 | 6.33 | 6.33 | ChEMBL |
| A2A | AA2AR | Human | Adenosine | A | pKi | 6.18 | 6.18 | 6.18 | ChEMBL |
| μ | OPRM | Human | Opioid | A | pKi | 5.65 | 5.65 | 5.65 | ChEMBL |
| 5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pKi | 8.26 | 8.26 | 8.26 | Drug Central |
| 5-HT2B | 5HT2B | Human | 5-Hydroxytryptamine | A | pKi | 8.27 | 8.27 | 8.27 | Drug Central |
| 5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pKi | 8.27 | 8.27 | 8.27 | Drug Central |
| α2A | ADA2A | Human | Adrenoceptors | A | pKi | 8.23 | 8.23 | 8.23 | Drug Central |
| α2B | ADA2B | Human | Adrenoceptors | A | pKi | 8.2 | 8.2 | 8.2 | Drug Central |
| α2C | ADA2C | Human | Adrenoceptors | A | pKi | 8.21 | 8.21 | 8.21 | Drug Central |
| D3 | DRD3 | Human | Dopamine | A | pKi | 8.23 | 8.23 | 8.23 | Drug Central |
| μ | OPRM | Human | Opioid | A | pKi | 8.25 | 8.25 | 8.25 | Drug Central |
| NK2 | NK2R | Human | Tachykinin | A | pKi | 8.24 | 8.24 | 8.24 | Drug Central |
| A2A | AA2AR | Human | Adenosine | A | pKi | 8.21 | 8.21 | 8.21 | Drug Central |
| A3 | AA3R | Human | Adenosine | A | pKi | 8.2 | 8.2 | 8.2 | Drug Central |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| NK2 | NK2R | Human | Tachykinin | A | pIC50 | 5.33 | 5.33 | 5.33 | ChEMBL |
| α2B | ADA2B | Human | Adrenoceptors | A | pIC50 | 5.91 | 5.91 | 5.91 | ChEMBL |
| α2C | ADA2C | Human | Adrenoceptors | A | pIC50 | 5.36 | 5.36 | 5.36 | ChEMBL |
| 5-HT1A | 5HT1A | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.26 | 5.26 | 5.26 | ChEMBL |
| α2A | ADA2A | Human | Adrenoceptors | A | pIC50 | 5.42 | 5.42 | 5.42 | ChEMBL |
| 5-HT2B | 5HT2B | Human | 5-Hydroxytryptamine | A | pIC50 | 5.17 | 5.17 | 5.17 | ChEMBL |
| 5-HT2C | 5HT2C | Human | 5-Hydroxytryptamine | A | pIC50 | 5.06 | 5.06 | 5.06 | ChEMBL |
| D3 | DRD3 | Human | Dopamine | A | pIC50 | 5.38 | 5.38 | 5.38 | ChEMBL |
| A3 | AA3R | Human | Adenosine | A | pIC50 | 6.08 | 6.08 | 6.08 | ChEMBL |
| A2A | AA2AR | Human | Adenosine | A | pIC50 | 5.93 | 5.93 | 5.93 | ChEMBL |
| μ | OPRM | Human | Opioid | A | pIC50 | 5.26 | 5.26 | 5.26 | ChEMBL |
| TSH | TSHR | Human | Glycoprotein hormone | A | Potency | 4.5 | 4.5 | 4.5 | ChEMBL |
| 5-HT1A | 5HT1A | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.28 | 8.28 | 8.28 | Drug Central |